Production of micronic particles of biocompatible polymer using supercritical carbon dioxide

Preparation of budesonide and budesonide-PLA microparticles using supercritical fluid precipitation technology

“…In addition, the process requires much lower operating temperatures, when compared to spray drying, thereby avoiding drug degradation [19]. There have been numerous studies using PCA to produce drug particles [19][20], superconductor particles [21], polymer particles [8,[14][15][22][23][24], and many other particles.…”

Recent Applications of Supercritical Fluid Technology to Pharmaceutical Powder Systems

“…Process parameters that may influence particle formation in GAS precipitation include the rate of expansion of the solution, the physico-chemical properties of the solvent and antisolvent type [15,16], the concentration of the solute [15,17,18], temperature [17,18], and agitation and stirring [14].…”

“…Bio-erodible polymers in- elude slow-degrading types of high molecular weight such as PLA [5,17,20,26,[69][70][71], and polycaprolactone [70], as well as faster-degrading copolymers such as poly (lactide-co-glycolic acid) (PLGA) [72]. Sub-micron to micron-sized particles of PLA were produced using near-critical or supercritical carbon dioxide as an antisolvent [20].…”

“…Sub-micron to micron-sized particles of PLA were produced using near-critical or supercritical carbon dioxide as an antisolvent [20]. Other studies have consistently precipitated PLA in the form of discrete microspheres throughout a broad range of operating conditions and solution concentrations [17,26,[69][70][71].…”

Hydrodynamics Influence on Particles Formation Using SAS Process

“…The application of supercritical fluids (SCF) as an alternative to the conventional precipitation processes has been an active field of research and innovation during the past two decades (Jung & Perrut, 2001;Martín& Cocero, 2008;Shariati &Peters, 2003).Through its impact on health care and prevention of diseases, the design of pharmaceutical preparations in nanoparticulate form has emerged as a new strategy for drug delivery. In this way, the technology of supercritical fluids allows developing micronized drugs and polymer-drug composites for controlled release applications; this also meets the pharmaceutical requirements for the absence of residual solvent, correct technological and biopharmaceutical properties and high quality (Benedetti et al, 1997;Elvassore et al, 2001;Falk& Randolph, 1998;Moneghini et al, 2001;Reverchon& Della Porta, 1999;Reverchon, 2002;Subramaniam et al, 1997;Yeo et al, 1993;Winters et al,1996), as well as giving enhanced therapeutic action compared with traditional formulations (Giunchedi et al, 1998;Okada& Toguchi, 1995). The revised literature demonstrates that there are two principal ways of micronizing and encapsulating drugs with polymers: using supercritical fluid as solvent, the RESS technique (Rapid Expansion of Supercritical Solutions); or using it as antisolvent, the SAS technique (Supercritical AntiSolvent); the choice of one or other depends on the high or low solubility, respectively, of the polymer and drug in the supercritical fluid.…”